Aflibercept
Aflibercept 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diabetic Retinopathy、Macular Edema。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- Abdulkadir Küçük
- Bayer
- Peking University People's Hospital
- 4D Molecular Therapeutics
- Yeungnam University College of Medicine
- EyeBiotech Ltd.
- Nantes University Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Turkey (Türkiye)、英国、中国、美国、Argentina、澳大利亚、Bulgaria、法国、德国、Hungary、Israel、意大利
正在招募患者的 Aflibercept 研究
Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study
不适用招募中Turkey (Türkiye)NCT07821450An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
不适用招募中英国NCT06315556Real-world Study of Aflibercept 8 mg in nAMD
不适用招募中中国NCT07640997Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
III 期招募中美国Argentina澳大利亚BulgariaNCT07064759Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
III 期招募中South KoreaNCT07389980A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
II 期招募中美国NCT07205887Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
不适用招募中法国NCT06271330STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
II 期招募中意大利NCT07213570High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
IV 期招募中美国NCT06662994Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
I 期招募中美国NCT06132035A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
III 期招募中美国NCT07705607Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
II 期招募中美国NCT07630649Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
不适用招募中GreeceNCT06929507Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
I 期 / II 期招募中美国NCT06047379Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
I 期 / II 期招募中中国NCT06672536Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
II 期招募中中国NCT07776522Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients
早期 I 期招募中中国NCT07362927A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
III 期招募中美国中国日本NCT078670804D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
I 期 / II 期招募中美国Puerto RicoNCT05197270Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
III 期招募中德国爱尔兰荷兰PolandNCT04663750Aflibercept and Bevacizumab for Diabetic Maculopathies
IV 期招募中IraqNCT06850571Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
III 期招募中中国NCT07317934Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
不适用招募中日本NCT04519619Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
II 期招募中美国NCT06942520
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。